Bagsværd, Denmark, 30 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.

Since the announcement of the programme, the following transactions have been made:

 Number of
B shares		Average
purchase price		Transaction
value, DKK
Accumulated, last announcement853,985 706,839,100
21 November 202282,073821.0867,388,728
22 November 202284,000825.2869,323,480
23 November 202285,000841.1271,494,810
24 November 202284,000842.5570,774,143
25 November 202284,000847.8871,222,209
28 November 202284,000855.8071,886,953
29 November 202283,000880.0373,042,270
Accumulated under the programme1,440,058 1,201,971,694

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 28,868,876 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 29 November 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 27,179,690 B shares at an average share price of DKK 786.81 per B share equal to a transaction value of DKK 21,385,373,749.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.

Contact for further information

Media: 
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors: 
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com		Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Company announcement no 87 / 2022

Attachments

  • CA221130_Share-repurchase
  • Transactions-221130